Abstract
Elevated focal adhesion kinase (FAK) expression occurs in advanced cancers, yet a signaling role for FAK in tumor progression remains undefined. Here, we suppressed FAK activity in 4T1 breast carcinoma cells resulting in reduced FAK Y925 phosphorylation, Grb2 adaptor protein binding to FAK, and signaling to mitogen-activated protein (MAP) kinase (MAPK). Loss of a FAK-Grb2-MAPK linkage did not affect 4T1 cell proliferation or survival in culture, yet FAK inhibition reduced vascular endothelial growth factor (VEGF) expression and resulted in small avascular tumors in mice. This FAK-Grb2-MAPK linkage was essential in promoting angiogenesis as reconstitution experiments using Src-transformed FAK-null fibroblasts revealed that point mutations affecting FAK catalytic activity (R454) or Y925 phosphorylation (F925) disrupted the ability of FAK to promote MAPK- and VEGF-associated tumor growth. Notably, in both FAK-inhibited 4T1 and Src-transformed FAK-null cells, constitutively activated (CA) mitogen-activated protein kinase kinase 1 (MEK1) restored VEGF production and CA-MEK1 or added VEGF rescued tumor growth and angiogenesis. These studies provide the first biological support for Y925 FAK phosphorylation and define a novel role for FAK activity in promoting a MAPK-associated angiogenic switch during tumor progression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- −/−:
-
null
- Ad:
-
adenovirus
- CA:
-
constitutively activated
- CAM:
-
chorioallantoic membrane
- Ctrl:
-
control
- DAB:
-
diaminobenzidine
- ERK:
-
extracellular signal-regulated kinase
- FAK:
-
focal adhesion kinase
- FRNK:
-
FAK-related non-kinase
- HUVEC:
-
human umbilical vein endothelial cell
- IVK:
-
in vitro kinase
- MEK1:
-
mitogen-activated protein kinase kinase 1
- PTK:
-
protein-tyrosine kinase
- pY:
-
phosphotyrosine
- SH2:
-
Src homology domain 2
- v-Src:
-
viral Src
References
Aguirre Ghiso JA . (2002). Oncogene 21: 2513–2524.
Barberis L, Wary KK, Fiucci G, Liu F, Hirsch E, Brancaccio M et al. (2000). J Biol Chem 275: 36532–36540.
Barr MP, Byrne AM, Duffy AM, Condron CM, Devocelle M, Harriott P et al. (2005). Br J Cancer 92: 328–333.
Benlimame N, He Q, Jie S, Xiao D, Xu YJ, Loignon M et al. (2005). J Cell Biol 171: 505–516.
Boudreau N, Myers C . (2003). Breast Cancer Res 5: 140–146.
Cance WG, Harris JE, Iacocca MV, Roche E, Yang X, Chang J et al. (2000). Clin Cancer Res 6: 2417–2423.
De S, Razorenova O, McCabe NP, O'Toole T, Qin J, Byzova TV . (2005). Proc Natl Acad Sci USA 102: 7589–7594.
Ding Q, Grammer JR, Nelson MA, Guan JL, Stewart Jr JE, Gladson CL . (2005). J Biol Chem 280: 6802–6815.
Eliceiri BP, Puente XS, Hood JD, Stupack DG, Schlaepfer DD, Huang XZ et al. (2002). J Cell Biol 157: 149–160.
Ferrara N, Gerber HP, LeCouter J . (2003). Nat Med 9: 669–676.
Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA . (1995). Science 270: 1500–1502.
Gabarra-Niecko V, Schaller MD, Dunty JM . (2003). Cancer Metastasis Rev 22: 359–374.
Golubovskaya V, Beviglia L, Xu LH, Earp III HS, Craven R, Cance W . (2002). J Biol Chem 277: 38978–38987.
Guo W, Giancotti FG . (2004). Nat Rev Mol Cell Biol 5: 816–826.
Hanahan D, Weinberg RA . (2000). Cell 100: 57–70.
Hanks SK, Ryzhova L, Shin NY, Brabek J . (2003). Front Biosci 8: 982–996.
Haskell H, Natarajan M, Hecker TP, Ding Q, Stewart Jr J, Grammer JR et al. (2003). Clin Cancer Res 9: 2157–2165.
Hauck CR, Hsia DA, Puente XS, Cheresh DA, Schlaepfer DD . (2002). EMBO J 21: 6289–6302.
Hecker TP, Gladson CL . (2003). Front Biosci 8: 705–714.
Heppner GH, Miller FR, Shekhar PM . (2000). Breast Cancer Res 2: 331–334.
Hood JD, Frausto R, Kiosses WB, Schwartz MA, Cheresh DA . (2003). J Cell Biol 162: 933–943.
Hsia DA, Mitra SK, Hauck CR, Streblow DN, Nelson JA, Ilic D et al. (2003). J Cell Biol 160: 753–767.
Ilic D, Almeida EA, Schlaepfer DD, Dazin P, Aizawa S, Damsky CH . (1998). J Cell Biol 143: 547–560.
Ilic D, Furuta Y, Kanazawa S, Takeda N, Sobue K, Nakatsuji N et al. (1995). Nature 377: 539–544.
Ilic D, Kovacic B, McDonagh S, Jin F, Baumbusch C, Gardner DG et al. (2003). Circ Res 92: 300–307.
Jiang BH, Agani F, Passaniti A, Semenza GL . (1997). Cancer Res 57: 5328–5335.
Kornberg LJ, Shaw LC, Spoerri PE, Caballero S, Grant MB . (2004). Invest Ophthalmol Vis Sci 45: 4463–4469.
Kranenburg O, Gebbink MF, Voest EE . (2004). Biochim Biophys Acta 1654: 23–37.
Lark AL, Livasy CA, Dressler L, Moore DT, Millikan RC, Geradts J et al. (2005). Mod Pathol PMID: 15861214.
Li N, Zhang Y, Naylor MJ, Schatzmann F, Maurer F, Wintermantel T et al. (2005). EMBO J 24: 1942–1953.
Lightfoot HM, Lark A, Livasy CA, Moore DT, Cowan D, Dressler L et al. (2004). Breast Cancer Res Treat 88: 109–116.
McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC . (2005). Nat Rev Cancer 5: 505–515.
McLean GW, Komiyama NH, Serrels B, Asano H, Reynolds L, Conti F et al. (2004). Genes Dev 18: 2998–3003.
Mitra SK, Hanson DA, Schlaepfer DD . (2005). Nat Rev Mol Cell Biol 6: 56–68.
Mitra SK, Lim S-T, Chi A, Schlaepfer DD . (2006). Oncogene, doi:10.1038/sj.onc.1209482.
Moissoglu K, Gelman IH . (2003). J Biol Chem 278: 47946–47959.
Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH et al. (1996). Science 272: 263–267.
Pages G, Pouyssegur J . (2005). Cardiovasc Res 65: 564–573.
Parsons JT . (2003). J Cell Sci 116: 1409–1416.
Peng X, Ueda H, Zhou H, Stokol T, Shen TL, Alcaraz A et al. (2004). Cardiovasc Res 64: 421–430.
Schlaepfer DD, Hunter T . (1997). J Biol Chem 272: 13189–13195.
Schlaepfer DD, Mitra SK . (2004). Curr Opin Genet Dev 14: 92–101.
Schlaepfer DD, Hanks SK, Hunter T, van der Geer P . (1994). Nature 372: 786–791.
Schlaepfer DD, Jones KC, Hunter T . (1998). Mol Cell Biol 18: 2571–2585.
Schlaepfer DD, Mitra SK, Ilic D . (2004). Biochim Biophys Acta 1692: 77–102.
Seko Y, Takahashi N, Sabe H, Tobe K, Kadowaki T, Nagai R . (1999). Biochem Biophys Res Commun 262: 290–296.
Shen T-L, Park AYJ, Alcaraz A, Peng X, Jang I, Koni P et al. (2005). J Cell Biol 169: 941–952.
Sieg DJ, Hauck CR, Schlaepfer DD . (1999). J Cell Sci 112: 2677–2691.
Slack JK, Adams RB, Rovin JD, Bissonette EA, Stoker CE, Parsons JT . (2001). Oncogene 20: 1152–1163.
Slack-Davis JK, Eblen ST, Zecevic M, Boerner SA, Tarcsafalvi A, Diaz HB et al. (2003). J Cell Biol 162: 281–291.
Storgard C, Mikolon D, Stupack DG . (2004). Methods Mol Biol 294: 123–136.
Tan C, Cruet-Hennequart S, Troussard A, Fazli L, Costello P, Sutton K et al. (2004). Cancer Cell 5: 79–90.
Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA et al. (2000). Nat Med 6: 529–535.
Tschan MP, Fischer KM, Fung VS, Pirnia F, Borner MM, Fey MF et al. (2003). J Biol Chem 278: 42750–42760.
van Nimwegen MJ, Verkoeijen S, van Buren L, Burg D, van de Water B . (2005). Cancer Res 65: 4698–4706.
Wang D, Grammer JR, Cobbs CS, Stewart JE, Liu Z, Rhoden R et al. (2000). J Cell Sci 113: 4221–4230.
Weaver VM, Peterson OW, Wang F, Larabell CA, Briand P, Damsky C et al. (1997). J Cell Biol 137: 231–245.
White DE, Kurpios NA, Zuo D, Hassell JA, Blaess S, Mueller U et al. (2004). Cancer Cell 6: 159–170.
Xu LH, Yang X, Bradham CA, Brenner DA, Baldwin Jr AS, Craven RJ et al. (2000). J Biol Chem 275: 30597–30604.
Acknowledgements
We thank Bruce Torbett (Scripps) for the pVIPER lentiviral vector, Luigi Naldini (San Raffaele Telethon Institute for Gene Therapy, Milan, Italy) for the CMVDR8.74 and VSVG lentiviral packaging vectors, Charlie Surh (Scripps) for Leica cryostat usage, Christof Hauck (University of Wuerzburg, Germany) for performing the initial soft agar growth assays, Jun-Lin Guan (Cornell) for sharing results prior to publication, and we greatly appreciate the administrative assistance provided by Theresa Villalpando. S Mitra is supported by a fellowship (12FT-0122) from the California Tobacco-Related Disease Research Program and D Hanson by an NIH Training grant (T32 AI07606). This work was supported by grants from the NIH to Dusko Ilic (CA087652), Dwayne Stupack (CA107263), David Cheresh (CA50286, CA45726, CA95262, EY14174, CA78045, HL57900) and to David Schlaepfer (CA75240, CA87038, CA102310). David Schlaepfer is an Established Investigator of the American Heart Association. This is manuscript number 17598-IMM from The Scripps Research Institute.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mitra, S., Mikolon, D., Molina, J. et al. Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors. Oncogene 25, 5969–5984 (2006). https://doi.org/10.1038/sj.onc.1209588
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1209588
Keywords
This article is cited by
-
Focal adhesion kinase: from biological functions to therapeutic strategies
Experimental Hematology & Oncology (2023)
-
C1GALT1 high expression is associated with poor survival of patients with pancreatic ductal adenocarcinoma and promotes cell invasiveness through integrin αv
Oncogene (2021)
-
Accumulation of tissue factor in endothelial cells promotes cellular apoptosis through over-activation of Src1 and involves β1-integrin signalling
Apoptosis (2020)
-
Zirconia stimulates ECM-remodeling as a prerequisite to pre-osteoblast adhesion/proliferation by possible interference with cellular anchorage
Journal of Materials Science: Materials in Medicine (2018)
-
Integrin beta8 (ITGB8) activates VAV-RAC1 signaling via FAK in the acquisition of endometrial epithelial cell receptivity for blastocyst implantation
Scientific Reports (2017)